Why is Remus Pharma. falling/rising?

As of 04-Sep, Remus Pharmaceuticals Ltd is currently priced at 883.00, reflecting a price increase of 2.4 (0.27%). Despite this slight uptick, the stock has been underperforming in the short term, with a one-week return of -1.15% and a one-month return of -1.88%. The stock is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. Additionally, there has been a significant decline in investor participation, as evidenced by a 50% drop in delivery volume compared to the 5-day average. Unfortunately, there is no information available regarding positive or negative factors that could provide further insight into the stock's recent movement.
In the broader market context, Remus Pharmaceuticals has not performed well compared to the Sensex, which has gained 0.95% over the past week. The stock's year-to-date decline of -29.29% starkly contrasts with the Sensex's increase of 4.61%, indicating a significant underperformance relative to the benchmark. This trend of underperformance is further highlighted by the stock's one-year return of -33.19%, while the Sensex has only decreased by 1.84%. Overall, the combination of poor short-term performance, declining investor interest, and a lack of positive market sentiment contributes to the challenges faced by Remus Pharmaceuticals in the current market environment.